ERBB2 and breast carcinoma: Next, to test if in HER2 breast and gastroesophageal cancers GSDMB is functionally involved in regulating drug response/resistance also to the HER2 tyrosine kinase inhibitor lapatinib, we used three HER2 + cancer cell lines that endogenously express GSDMB, HCC1954 (breast cancer), OE19 (esophageal) and NCI-N87 (gastric).